17 - 21 June 2017
Helsinki, Finland

Industry Programme

Company Sponsored Symposia


Sunday, 18 June 2017


Company Sponsored Symposium (CSS 1)
Thermo Fisher Scientific
Hall 1
The story of IgE – The next 50 years

Chair: SGO Johansson, Sweden

The molecular allergology revolution – Components and microarrays in prediction of allergic diseases
Marianne van Hage, Sweden

IgE and IgG4 antibodies to specific proteins in allergy, asthma and eosinophilic esophagitis
Thomas Platts-Mills, United States

Food allergy-induced anaphylaxis – allergen components and cofactors
Victoria Cardona, Spain

Diagnostic tools in insect venom allergy - State of the art and future directions
Thilo Jakob, Germany

Company Sponsored Symposium (CSS 2)
Novartis Pharma AG
Hall 3a
As if severe allergic asthma wasn´t enough: associated and treatment-induced comorbidities

Chair: Jean Bousquet, France

Update on allergic sub-phenotypes
Jean Bousquet, France

Pathological mechanisms of allergy in asthma and comorbidities: a central role for IgE
Oscar Palomares, Spain

Uncovering nasal polyps, where are we?
Claus Bachert, Belgium

Navigating corticosteroid induced comorbidities in patients with SAA
Matthias Blueher, Germany

Re-addressing SAA treatment: summarizing the omalizumab evidence in children and adults
Nikos Papadopolous, United Kingdom

Company Sponsored Symposium (CSS 3)
STALLERGENES GREER
Room 101
Long term evidence of SLIT: do we have a breakthrough in 2017?

Chaired by Linda Cox, United States
Antonella Muraro, Italy

Introduction: Long term evidence of SLIT
Antonella Muraro, Italy

Allergic sensitization and the atopic march: natural progression and long term SLIT targets
Paolo M. Matricardi, Germany

How far does the clinical trial evidence takes us to prove SLIT’s long term effects?
Linda Cox, United States

Finding the breakthrough in real world evidence?
Stefan Zielen, Germany & Ulrich Wahn, Germany

Conclusion: Do we have a breakthrough in 2017?
Linda Cox, United States


Monday, 19 June 2017

Company Sponsored Symposium (CSS 4)
Mylan
Hall 5a
The allergic rhinitis challenge: perception, control and real-life effectiveness

Chairman’s Introduction
Erkka Valovirta, Finland

Changing the perception of the AR problem: barriers and solutions
Mike Bewick, United Kingdom

A simplified way to manage AR: do you agree with the experts?
Jean Bousquet, France

AR control in real life: the next battle field
Magnus Wickman, Sweden

Discussion and wrap-up
All

Company Sponsored Symposium (CSS 5)
HAL Allergy
Hall 3a
Roadmap of Innovative and Registered Allergen Immunotherapy


Chairs: Oliver Pfaar, Germany
Dirk-Jan Opstelten, The Netherlands

Introduction – Insights to AIT Clinical Study Program
Dirk-Jan Opstelten, The Netherlands

The TAV Program – Implications for the Allergologist in Europe
Ludger Klimek, Germany

Grass allergen immunotherapy – Where we are
Moisés Calderón, United Kingdom

Birch or Trees – From Allergen Source to Immunological Active Compounds
Krzysztof Kowal, Poland

Clinical Development of Immunotherapy for Peanut Allergy
Carsten Bindslev-Jensen, Denmark

Company Sponsored Symposium (CSS 6)
Uriach
Hall 3d
Consolidated strategies in the management of allergies

Chairs’ welcome and introduction
Torsten Zuberbier, Germany
Marek L. Kowalski, Poland

Lectures
What’s new in ARIA and Urticaria guidelines?
Torsten Zuberbier, Germany

The added value of Rupatadine in children
Paraskevi Xepapadaki, Greece

Rupatadine: a safe choice in the treatment of allergies
Joaquim Mullol, Spain

Discussion and concluding remarks
Moderated by Torsten Zuberbier, Spain and Marek L. Kowalski, Poland


Tuesday, 20 June 2017

Company Sponsored Symposium (CSS 7)
ALK
Hall 5a
Step into the future of paediatric respiratory allergic disease

Chairs: Mika Mäkelä, Finland
Eckard Hamelmann, Germany

What can the HDM SLIT-tablet offer adolescents living with HDM allergic rhinitis?
Michael S Blaiss, United States

HDM allergic asthma - addressing the unmet needs in children and adolescents
Carmen Vidal, Spain

Benefits of early intervention to prevent asthma in children with hayfever
Graham Roberts, United Kingdom

Company Sponsored Symposium (CSS 8)
Allergopharma GmbH & Co. KG
Hall 3g
FASIT (Future of the Allergists and Specific Immunotherapy) meets EAACI: Novel Patient Profiling, Promising Treatments and Regulatory Challenges

Chairs: Marek Jutel, Poland
Ulrich Wahn, Germany

New Promising Perspectives in AIT
Marek Jutel, Poland

Molecular Approaches for AIT - the Peril of Phase III Trials
Jörg Kleine-Tebbe, Germany

The Use of AIT in Europe - Regulatory Aspects and Call for Harmonization
Oliver Pfaar, Germany

How can we offer High Quality Diagnostics for our Patients in the Future?
Piotr Kuna, Poland